Back
Prothena Corp PLC 10K Form
Sell
22
PRTA
Prothena Corp PLC
Last Price:
14.43
Seasonality Move:
-2.34%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-08 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2024-02-22 | 10K | PRTA/Prothena Corp PLC Annual |
2023-11-02 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2023-08-03 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2023-05-04 | 10Q | PRTA/Prothena Corp PLC Quarterly |
2023-02-28 | 10K | PRTA/Prothena Corp PLC Annual |
Receive PRTA News And Ratings
See the #1 stock for the next 7 days that we like better than PRTA
PRTA Financial Statistics
Sales & Book Value
Annual Sales: | $91.37M |
---|---|
Cash Flow: | $-45.2M |
Price / Cash Flow: | 0 |
Annual Sales: | $9.93 |
Price / Book: | 1.36 |
Profitability
EPS (TTM): | -2.48000 |
---|---|
Net Income (TTM): | $-131.83M |
Gross Margin: | $0 |
Return on Equity: | -23.56% |
Return on Assets: | -19.93% |
Prothena Corp PLC Earnings Forecast
Key Prothena Corp PLC Financial Ratios
- The Gross Profit Margin over the past 5 years for PRTA is 0.00%.
- The Selling, General & Administrative Expenses for PRTA have been equal to 67.68% of Gross Profit Margin.
- The Research & Development expenses have been 241.40% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of PRTA is -160.91% of Total Revenues.
- Per Share Earnings over the last 14 years have been positive in 6 years.
Prothena Corp PLC Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | PRTA |
CUSIP: | G72800 |
Website: | prothena.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 11.52 |
Quick Ratio: | 11.19 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
PRTA Technical Analysis vs Fundamental Analysis
Sell
22
Prothena Corp PLC (PRTA)
is a Sell
Is Prothena Corp PLC a Buy or a Sell?
-
Prothena Corp PLC stock is rated a Sell
The current Prothena Corp PLC [PRTA] share price is $14.40. The Score for PRTA is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.